
How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?
How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?
The composition of the gut microbiome is easily disrupted by antibiotics, leaving the host susceptible to further infection or other disturbance of gut flora that can lead to both short- and long-term deleterious effects.
In results of a national survey, investigators pieced together a look at the psychological toll of the pandemic on physicians and identified the biggest stressors.
The CovidIQ tool successfully predicted a COVID-19 spike in Jacksonville, Florida, a full 2 weeks before it was recognized by the Florida Department of Health.
Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics
RHB-105 is an “all-in-one” fixed-dose oral capsule comprising rifabutin 50 mg, amoxicillin 1000 mg, and omeprazole 40 mg.